ZURICH (Reuters) - Novartis is exiting drug discovery at its Shanghai site and shifting its focus to drug development, saying accelerating approvals in China are pushing the Swiss company to dedicate ...
In particular, Aradhye noted "increasing progress" at all levels of the innovation supply chain in China — "whether it's ...
Announcing two licensing deals with Swiss pharma giant Novartis AG, Shanghai-based Argo Biopharmaceutical Co. Ltd. said on Jan. 7 that it stands to gain up to $4.165 billion for two of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results